Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AREDS II update

This article was originally published in The Tan Sheet

Executive Summary

The National Eye Institute has enrolled 2,907 people aged 50 to 85 years with high risk of advanced macular degeneration to participate in the Age Related Eye Disease Study II, and researchers expect to complete enrollment by April, according to Dr. Traci Clemons at the SupplySide West trade show in Las Vegas Nov. 6. Clemons, senior statistician for the EMMES Corporation, the firm overseeing the study, updated seminar attendees on the the study's progress, which aims to evaluate the efficacy of lutein and zeanxanthin and/or lutein and zeanxanthin in combination with omega-3 fatty acids on progression to AMD (1"The Tan Sheet" Jan. 9, 2006, In Brief). Researchers will enroll approximately 4,000 subjects and conclude the study in 2013, five years after the last patient is enrolled...
Advertisement

Related Content

NIH lutein study

Topics

Advertisement
UsernamePublicRestriction

Register

PS101102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel